Low-dose rtPA
Phase 3Small molecule
Low-dose rtPA is one of 63 small molecule programs targeting Stroke. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Low-dose rtPA
TThe George Institute
Phase 3
Edarbi
TakedaPreclinical
Benicar
NovartisPreclinical
Apresoline
NovartisPreclinical
Zebeta
TevaPreclinical
Edarbi
TakedaPreclinical
Aceon
Institut de Recherches Internationales ServierPreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Avastin
BBio-Thera Solutions
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Low-dose rtPA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TThe George Institute